The effect of Heyan Kuntai Capsule Combined with Hormone Replacement Therapy on the Premature Ovarian Insufficiency

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800017774

Enrollment

Unknown

Registered

2018-08-13

Start date

2018-09-04

Completion date

Unknown

Last updated

2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature Ovarian Insufficiency

Interventions

Group A:Femoston

Group B:Heyan Kuntai capsule

Group C:Kuntai capsule plus Femoston

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: (1) 18~40 years old; (2) Meet the diagnosis standard of premature ovarian insufficiency; (3) Intend to treatment.

Exclusion criteria

Exclusion criteria: (1) substance such as cigarettes, alcohol or drug abuse in the past 3 months; (2) BMI=32kg/m2 of BMI=18.5kg/m2; (3) the history of ovariectomy or hysterectomy; (4) undergoing acute inflammation; (5) combined with serious diabetes (6) combined with serious osteoporosis (7) combined with serious cardiovascular and cerebrovascular diseases, lung or kidney disorders, or mental illness; (8) treated with estrogen, progesterone, androgen or other medicines for menopausal syndrom; (9) allergy to the medicines in this study; (10) patients involved in an ongoing clinical trial; (11) those the researchers considered unsuitable for this study.

Design outcomes

Primary

Measure	Time frame
basal serum sex hormones;Kupperman Index;	—

Secondary

Measure	Time frame
bone mineral density;serum TC, TG, HDL-C, LDL-C;serum P1NP, ß-CTX, ALP, Ca, P;	—

Countries

China

Contacts

Public ContactXiaodong Li

The Second Hospital, Hebei Medical University

709866384@qq.com+86 13933160139

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 28, 2026